AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 1 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - According to doctors in Italy, interferon (IFN)-alpha or endostatin gene transfer hamper angiogenesis in murine models of human breast cancers and do so more effectively than angiostatin gene transfer.
The doctors work at the University of Padova in Italy, where they compared the effects of delivering angiostatin, endostatin, and IFN-alpha(1) with at least two human breast cancer cell lines (MCF7 and MDA-MB435) using Moloney leukemia virus-based retroviral vectors. Each type of transferred gene is known to convey angiogenic inhibition when delivered to cells in gene therapy.
Initially, S. Indraccolo and other members of the investigation team transduced the two breast cancer cell lines with each of the three different genes and checked for cellular expression of recombinant protein.
"Their production did not impair in vitro growth of these breast cancer cells nor their viability, and did not interfere with the expression of angiogenic factors," said Indraccolo and colleagues.
Still, supernatant from the transduced cells did stop endothelial cell growth and migration, researchers indicated.
In vivo, IFN-alpha(1) gene transfer affected MCF7 and MDA-MB435 tumors growing in nude mice by controlling angiogenesis, whereas endostatin gene transfer only affected the ...
Source: HighBeam Research, Interferon and endostatin gene therapy outpace angiostatin in breast...